Akademik Veri Yönetim Sistemi
Balkan Journal Of Medical Genetics, cilt.22, sa.2, ss.25-30, 2019 (SCI-Expanded)
Doxorubicin is one of the most commonly used chemotherapeutic agentsfor adjuvant chemotherapy of breast
cancer. In the studies focused on finding biomarkers to
predict the response of the patients and tumorsto the drugs
used, the Twist transcription factor has been suggested as
a candidate biomarker for predicting chemo-resistance of
breast tumors. In thisstudy, we aimed to investigate the relationship between TWIST transcription factor expression
and the effectiveness of doxorubicin treatment on directly
taken primary tumor samples from chemotherapy-naive
breast cancer patients. Twenty-six primary breast tumor
samples taken from 26 different breast cancer patients
were included in this study. Adenosine triphosphate tumor chemo-sensitivity assay (ATP-TCA) has been used
to determine tumor response to doxorubicin and real-time
reverse-transcription polymerase chain reaction (RT-PCR)
was used for analyzing the TWIST1 gene expression of
tumors. There was a significant difference in TWIST gene
expression between responder and non respondertumors(p
<0.05). The TWIST gene expression of the drug-resistant
group was higher than the responsive group. This difference was not dependent on the histopathological features
of tumors. In conclusion, compatible with earlier studies
that have been performed with cell lines, the currentstudy
supports the role of higher TWIST gene expression as a
biomarker for predicting the response of breast tumors to
chemo-therapeutic agent doxorubicin.
Keywords: Biomarker; Breast cancer; Chemotherapy; Expression; TWIST1 gene.